

JOHN WADE McKEOWN, M.D.

CURRICULUM VITAE

Professor of Medicine
University of Kentucky Medical Center
Department of Internal Medicine
Division of Nephrology, Bone & Mineral Metabolism
C422, 4th Floor Transplant Center
800 Rose Street Lexington, KY 40536

VA Medical Center
Renal Section (111J)
Cooper Drive Division
Lexington, KY 40511

I. PERSONAL DETAILS:

Certifications: Internal Medicine - 1977
Board Eligible - Nephrology

II. EDUCATION:

High School: 1962-66 Father Ryan High School
Nashville, Tennessee

Undergraduate College: 1966-70 B.A. Vanderbilt University
Nashville, Tennessee

Professional School: 1970-73 M.D. University of Tennessee
College of Medicine
Memphis, Tennessee

III. PROFESSIONAL EXPERIENCE:

Jan - Jun 1974 Fellow in Nephrology
University of Tennessee
Memphis, Tennessee

1974 – 1975 Intern (Medicine)
Duke University Medical Center

Durham, North Carolina

1975 – 1976
Junior Assistant Resident
Department of Medicine
Duke University Medical Center
Durham, North Carolina

1976 – 1977
Senior Assistant Resident
Department of Medicine
Duke University Medical Center
Durham, North Carolina

1977 – 1979
Research Fellow
Division of Nephrology
Duke University Medical Center
University of Tennessee
Memphis, Tennessee

July - Dec 1979
Clinical Fellow
Division of Nephrology
Duke University Medical Center
Durham, North Carolina

IV. ACADEMIC APPOINTMENTS

Jan 1980 - June 1984
University of Michigan Medical Center
Assistant Professor of Internal Medicine
Ann Arbor, Michigan

July 1984 - June 1994
University of Kentucky Medical Center
Assistant Professor of Internal Medicine

July 1994 - June 2003
University of Kentucky Medical Center
Associate Professor of Internal Medicine

July 2003 - present
University of Kentucky Medical Center
Professor of Internal Medicine

V. HOSPITAL APPOINTMENTS:

Jan 1980 - June 1984	Attending Physician University of Michigan Hospital and Ann Arbor VA Medical Center
July 1984 – present	Attending Physician, U.K. Medical Center Attending Physician, Lexington VAMC
July 1989 – present	Transplant Physician - U.K.M.C. Renal Transplant Program
March 1992 - present	Transplant Physician - U.K.M.C. Heart, Lung and Heart-Lung Transplant Program

VI. TEACHING ACTIVITIES:

1984 – present	Lecturer, Introduction to Clinical Medicine Course
1986 – 1988	Participant, Family Medicine Review Course
1987 – present	Lecturer, Acute Care Lecture Series
1988 – present	Lecturer, Pathology 821
Attending Rounds:	U.K. Nephrology Service U.K. Renal Consult Service V.A. Medical Wards
7/89 - 7/92	Director - Nephrology Grand Rounds and Biopsy Conference
7/89 – present	Morning Report, VAMC

VII. TEACHING PRESENTATIONS:

- May 31, 1986. Medical House Staff Conference. "Nephrotic Syndrome"
- July 18, 1986. Medical House Staff Conference. "Acute Renal Failure"
- July 8, 1987. Medical House Staff Conference. "Acute Renal Failure"

Oct. 28, 1987. Medical House Staff Conference. "Rapidly Progressive Glomerulonephritis"

July 11, 1988. Acute Care Conference. "Acute Renal Failure"

April 3, 1989. Noon Conference. "Renal Tubular Acidosis"

Aug. 2, 1989. Acute Care House Staff Conference. "Acute Renal Failure"

Nov. 1, 1989. Medical Grand Rounds. "Rapidly Progressive Glomerulonephritis and Pulmonary Renal Syndrome"

Nov. 21, 1989. Noon Conference. "Renal Tubular Acidosis"

Nov. 1989. Renal Workshop. Pathology 821

May 1990. Discussion of Acid-Base Cases with Physiology Medical Students.

Aug. 2, 1990. Acute Care House Staff Lecture Series. "Acute Renal Failure"

Oct. 26, 1990. House Staff Conference. "Renal Tubular Acidosis"

Aug. 13, 1991. House Staff Conference. "Acute Renal Failure"

Nov. 15, 1991. House Staff Conference. "Approach to Renal Disease"

Mar. 13, 1992. House Staff Conference. "Diabetic Nephropathy"

Apr. 27, 1992. House Staff Conference. "Renal Transplantation"

Aug. 3, 1992. House Staff Conference. "Acute Renal Failure"

Jan. 26, 1992. House Staff Conference. "Renal Tubular Acidosis"

May 26, 1993. Medicine Grand Rounds. "Organ Procurement: From Donor to Recipient"

Oct. 8, 1993. House Staff Conference. "Diabetic Nephropathy: Pathogenesis, Natural History, and Prevention"

August, 1997. Cardio-Thoracic Grand Rounds. "Transplant Immunosuppression"

July 1998 Housestaff Teaching Conference. "Potassium Disorders"

August 1998 Housestaff Conference "Acute Renal Failure"

October 1999 Pulmonary Critical Care Conference. “Continuous Renal Replacement Therapy”

August 2000 Housestaff Conference. “Acute Renal Failure”

February 2001 Pulmonary Critical Care Conference. “Acute Renal Failure”

August 2001 Urology Resident Conference. “Review of Renal Physiology”

August 2001 Urology Resident Conference. “Transplantation Immunology”

August 2001 Housestaff Conference. “Acute Renal Failure

October 2001 Fellow Teaching Conference. “Renal Tubular Transport Physiology”

July 2002 Housestaff Conference. “Acute Renal Failure”

August 2003 Housestaff Conference. “Acute Renal Failure”

VIII. ADVISING ACTIVITY:

Advisor - Dept. of Medicine Residents

IX. ADMINISTRATIVE ACTIVITY:

7/84 - 6/89 Director, Dialysis Unit, Lexington
VA Medical Center

7/89 – 7/05 Assistant Chief, Medical Service
Lexington VA Medical Center

11/05 – present Acting Chief, Renal Section,
Lexington VA Medical Center

Committees:

1985 – 1988 Member, Research and Development
Committee, VA Medical Center

1987 – 1988 Member, Institutional Finance and
Resource Allocation Committee of the
University Senate

1988 – present Member, Graduate Medical Education

	Committee
1988 – present	Member, Department of Medicine Internship Selection Committee
1992 – present	Heart Lung Transplant Patient Evaluation Committee
1992 – present	Commodity Standardization Committee, VA Medical Center
1989 – present	Clinical Executive Board, VAMC (Alternate)
1997 – present	Transplant Center Executive Committee

X. HONORS:

Phi Beta Kappa

Alpha Omega Alpha

Thompson/DeSimone Award for Morning Report Teaching - 1988-89

Outstanding Faculty Teacher, 1988-89
(Awarded by Dept. of Medicine House Staff)

Chief Resident Award, Faculty of the Year 2003-2004

Chief Resident Award, Faculty of the Year 2004-2005

XI. EDITORIAL BOARD:

Clinical Nephrology

Reviewer: Journal of Heart and Lung Transplantation

XII. PROFESSIONAL ACTIVITY

Membership In Professional Societies: American College of Physicians

International Society of Nephrology, 1981

American Society of Nephrology

International Society of Heart and Lung Transplantation

American Society of Transplantation

XIII. RESEARCH/CREATIVE PRODUCTIVITY/PUBLICATIONS

ARTICLES:

1. McKeown, JW, PC Brazy and VW Dennis: Intrarenal heterogeneity for fluid, phosphate and glucose absorption in the rabbit. *Amer J Physio* 237(4): F312, 1979 or *Amer J Physiol: Renal Fluid Electrolyte Physio* 6(4):F312-F318, 1979.
2. Dennis, VW, PC Brazy and JW McKeown: Phosphate transport in isolated and perfused renal tubules. Fourth International Workshop on Phosphate and Other Minerals. Strasboug, France, June 1979 and *Adv Exp Med Biol* 128:25-35, 1980.
3. Brazy, PC, JW McKeown, RH Harris and VW Dennis: Comparative effects of dietary phosphate, unilateral nephrectomy and parathyroid hormone on phosphate transport by rabbit proximal tubules. *Kidney Int* 17:788-800, 1980.
4. McKeown, JW Disorders of Total Body Sodium in Fluids and Electrolytes, Kokko, JP and Tannen, RL, eds. WB Saunders, Philadelphia: 1985.
5. Lucas, BA, TH Waid, JS Thompson, SA Brown, LC Munch, JW McKeown, RJ Kryscio and RJ Prebeck: Comparison of T10Bg.1A-31 and OKT3 in Treating Acute Renal Allograft Rejection. *Transplantation Proceedings* 25(1):543-545, 1993.
6. Kidwell, DT, JW McKeown, JS Grider, GB McCombs, BA Jackson and CE Ott: Acute effects of gentamicin on thick ascending limb function in the rat. *European Journal of Pharmacology* 270:97-103, 1994.
7. Waid, TH, BA Lucas, JS Thompson, JW McKeown, S Brown, and L Jackson. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: Final analysis of a phase II clinical trial. *Transplantation* 64(2), 1997.
8. Brown, SA, BA Lucas, TH Waid, JW McKeown, S Barve, LR Jackson, and JS Thompson. T10B9 (MEDI-500) Mediated immunosuppression: Studies on the mechanism of action. *Clinical Transplantation*, December 1996.

9. Waid, TH, JS Thompson, JW McKeown, SA Brown, and ME Sekela. Induction immunotherapy in heart transplantation with T10B9.1A-31: a phase I study. *J Heart Lung Transp* 16:913-916, 1997.
10. Waid, TH, and JW McKeown: Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. *Transplantation Proc* 27(No. 5):46, 1995.
11. Brown, SA, BA Lucas, TH Waid, JW McKeown, M Tsuchida, and JS Thompson. T10B9 Action: The effect of anti-T-Cell antibody mitogenicity and graft rejection on the first dose cytokine response. *Transplantation Proc*, Vol 29: 315-316, 1997.
12. Thompson, JS, SA Brown, PI Hensley-Downey, BA Lucas, TH Waid, and JW McKeown: T10B9.1A-31 anti-human alpha/beta T-cell receptor antibody. *Recent developments in transplantation medicine*. Glenview, IL, Physicians and Scientists Publishing Co., 1995.
13. Hirschberg R, J Kopple, P Lipsett, E Benjamin, J Minel, T Albertson, M Munger, M Metzler, G Zalaga, M Murray, S Lowry, J Conger, W McKeown, M O'Shea, R Baughman, K Wood, M Haupt, R Kaiser, H Simms, D Warnock, W Summer, R Hintz, B Myers, K Haenftling, W Capra, M Pike and H-P Guler: Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. *Kidney International* 55:2423-2432, 1999.
14. Reddy, KS, D Stablein, S Taranto, R J Stratta, TD Johnston, TH Waid, JW McKeown, BA Lucas and D. Ranjan: Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type I diabetes mellitus and renal failure. *Transplantation Proceedings*, 33, 1659-1660, 2001
15. Tim Ruff, M.D., K. Sudhakar Reddy, M.D., Thomas D. Johnston, M.D., Thomas WAID, M.D., Wade McKeown, M.D., Taqi Kahn, M.D., Dinesh Ranjan, M.D., Bruce Lucas, M.D., Transplantation of pediatric en bloc cadaver kidneys into adult recipient: A Single-Center Experience. *Am Surg* 68: 1-3, 2002.
16. Butros, R., Reddy, K.S., Johnston, T.D., Kahn, T., WAID, T.H., McKeown, J.W., Sawaya, P.Ranjan, D., and Lucas, B.A. Successful renal transplantation using kidneys from diabetic cadaver donors. Submitted to *Clinical Nephrology*, June 2002.
17. Tuteja, S., Reddy, K.S., Johnston, T.D., Waid, T.H., et al. Prevention of acute rejection in recipients of pancreas transplantation using T10B9: A Pilot Study. Submitted to *Am. J. Transplant*, 2002.
18. Reddy K.S., Stablein D., Taranto S., Stratta R.J., Johnston T.D., WAID T.H., McKeown J.W., Lucas B.A., Ranjan D. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. *Am J Kidney Dis* 41(2):464-70, 2003.

19. Romero A.L., Reddy K.S., Johnston T.D., WAID T.W., McKeown J.W., Lucas B.A., Ranjan D. Simultaneous kidney-pancreas transplantation in a patient with small lymphocytic lymphoma. *Transplantation* 75(3):414-6, 2003.
20. Reddy, K.S., Davies, D., Ormond, D., Tuteja, S., Lucas, B.A., Johnston, T.D., WAID, T.H., McKeown, J.W., and Ranjan, D. Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation. *Am. J. Transplantation* 3(4):439-44, 2003.
21. Reddy K.S., Mastrangelo M.D., Johnston T. Khan T., WAID T., McKeown W., Lucas B., Ranjan D. Recipient outcome following living donor kidney transplantation using kidneys procured laparoscopically. *Clin Transplant* 17 Supple 9:44-7, 2003.

ABSTRACTS:

1. *McKeown, JW, PC Brazy and VW Dennis: Axial heterogeneity of phosphate transport along proximal convoluted tubules: Influence of phosphate restriction. *Kidney Int* 14:641, 1978.
2. Brazy, PC, JW McKeown and VW Dennis: Mechanisms of cyclic AMP-induced inhibition of proximal fluid absorption. *Kidney Int* 14:752, 1978.
3. *McKeown, JW, PC Brazy and VW Dennis: Axial and internephronal heterogeneity of transport processes in the rabbit proximal convoluted tubule. *Clin Res* 26:781A, 1978.
4. *McKeown, JW, PC Brazy and VW Dennis: Axial and inter-nephronal heterogeneity for fluid and phosphate absorption in rabbit proximal convoluted tubules. *Clin Res* 27:424A, 1979.
5. Dennis, VA, PC Brazy and JW McKeown: Phosphate transport in isolated and perfused renal tubules. *Min Elec Metab* 2:221, 1979.
6. *McKeown, JW: Effects of luminal lanthanum on fluid and phosphate transport in rabbit proximal convoluted tubule. *Clin Res* 30:458A, 1982.
7. *McKeown, JW: Effects of calcium ionophore A23187 on fluid and phosphate reabsorption in rabbit proximal convoluted tubules. *Kidney Int* 23:106, 1983.
8. McKeown, JW: Effects of cholinergic stimulation of fluid transport in rabbit proximal convoluted tubules. *Clin Res* 31:436A, 1983.
9. *Laughry, EG and JW McKeown: Effects of luminal addition of gentamicin on fluid and phosphate transport in rabbit proximal convoluted tubules. *Kidney Int* 25:147, 1984.

10. McKeown, JW: Evidence that cholinergic inhibition of proximal tubular fluid transport is calmodulin dependent. *Kidney Int* 25:310, 1984.
11. *Shumway, JA and JW McKeown: Direct effect of acetylcholine on fluid transport in rabbit proximal convoluted tubules. *Kidney Int* 25:315, 1984.
12. *McKeown, JW: Evidence for involvement of luminal membrane phospholipids in the inhibitory effect of parathyroid hormone (PTH) on transport in rabbit proximal convoluted tubules. *Kid Int* 27:122, 1985.
13. *Laughry, EG and JW McKeown: Blockade on luminal calcium entry blocks the inhibitory effect of dibutyl cAMP (DBcAMP) on fluid reabsorption (J_v) in rabbit PCT. *Kid Int* 27:120, 1985.
14. *McKeown, JW and G Goranflo: Evidence that the Effects of Angiotensin II on proximal tubular fluid reabsorption are dependent on extracellular calcium and lipoxygenase pathway products. *Kid Int* 31:279, 1987.
15. McKeown, JW: Direct Effect of Beta Endorphin on Fluid Reabsorption in Rabbit Proximal Convoluted Tubules. *Kid Int* 33:275, 1988.
16. *Sekela, ME, TH Waid, JW McKeown and NK Burki: Single Lung Transplantation at the University of Kentucky. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease, March 1993.
17. Waid, TH and JW McKeown: Treatment of Cytomegalovirus Disease with CMV Ig In Three Renal Transplantation Patients. *JASN* 4:966, 1993.
18. Sekela, ME, TH Waid, JW McKeown and NK Burki: Single lung transplantation at the University of Kentucky. 38th Annual Kentucky Thoracic Society Scientific Conference on Pulmonary Disease, March 1993.
19. *Sekela, ME, C Taylor, TH Waid, JW McKeown, R Berger and NK Burki: Single lung transplantation at the University of Kentucky. Presented at the annual meeting of the Kentucky Thoracic Society, Louisville, KY, 1994.
20. *Waid, TH, BA Lucas, JS Thompson, JW McKeown, and SA Brown: Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Accepted for presentation at the American Society of Transplant Physicians 13th Annual Meeting, Chicago, May 1994.
21. Brown, SA, BA Lucas, TH Waid, and JW McKeown: Human cytokine release following the first dose of either OKT3 or T10B9.1A31 in an in vivo SCID-human mouse model system. Submitted to the American Society of Transplant Physicians Annual Meeting, Chicago, IL, 1994.

22. Waid, TH, BA Lucas, JS Thompson, JW McKeown, and SA Brown: T10B9.1A31 effectively reverses renal allograft rejection rises with fewer side effects, less cytokine release and no severe infections. *JASN* 5:1042, 1994.
23. Waid, TH, BA Lucas, JS Thompson, JW McKeown, and SA Brown: Improved graft and patient survival with T10B9.1A31 or OKT3 monoclonal antibody for treatment for primary rejection. *JASN* 5:1442, 1994.
24. Brown, SA, JS Thompson, BA Lucas, ME Sekela, TH Waid, and JW McKeown: IL-10 induction by T10B9.1A31 or OKT3 anti-T cell therapy in kidney and heart transplant recipients. *JASN* 5:827, 1994.
25. Waid, TH, ME Sekela, JS Thompson, JW McKeown, and LR Jackson: Induction therapy with T10B9.1A31 is equivalent to OKT3 in cardiac allograft recipients. Submitted to the International Society for Heart and Lung Transplantation 15th Anniversary Meeting, April 1995.
26. Sekela, ME, NK Burki, R Berger, TH Waid, and JW McKeown: Liberalizing donor criteria for single lung transplant. Presented at the International Society of Heart Lung Transplantation Annual Conference, 1995.
27. Sekela ME, NK Burki, R Berger, JW McKeown, and TH Waid: University of Kentucky lung transplantation: a recipient limited program. Submitted to the Kentucky Thoracic Society Annual Meeting, 1995.
28. Waid TH, JS Thompson, BA Lucas, and JW McKeown: Severe infection occurs less frequently in renal allograft recipients treated for rejection with T10B9.1A-31 than in OKT3-treated patients. Presented at the First Annual Symposium on Controversies in Transplant Infection, Tucson, AZ, February 1995.
29. Waid TH, ME Sekela, JW McKeown, C Taylor, and S Little: Cytolytic induction therapy does not increase the risk of cytomegalovirus disease in lung transplantation recipients treated with Cytogam and Acyclovir. Presented at the First Annual Symposium on Controversies in Transplant Infection, Tucson, AZ, February 1995.
30. Waid TH and JW McKeown: CMB Ig successfully treats cytomegalovirus disease refractory to ganciclovir in renal transplant patients. Presented at the First Annual Symposium on Controversies in Transplant Infection, Tucson, AZ, February 1995.
31. Waid TH, JS Thompson, BA Lucas, and JW McKeown: Severe infection occurs less frequently in renal allograft recipients treated for rejection with T10B9.1A-31 than in OKT3-treated patients. *JASN* 6(3):1120, 1995.
32. Sudhaker R, T Johnston, L Thacker, T Waid, J McKeown, J Thompson, B Lucas and D Ranjan: Analysis of causes of graft failure after cadaveric kidney transplantation

compared to living unrelated donor kidney transplantation. Transplantation 67(9), S585, 1999.

33. Sudhaker R, L Thacker, T Johnston, T Waid, J McKeown, J Thompson, B Lucas and D Ranjan: Is cadaver donor a risk factor for acute rejection? Transplantation 67(9),S620,1999.

34 Ruff,T. S Reddy, T Johnston, T Waid, J McKeown, D Ranjan and B Lucus: Transplantation of pediatric en bloc cadaver kidneys in to adult recipients: a single center experience. Marshall University Research Day, Huntington, March 2001

35 Reddy, K S, D Stablin, S Taranto, M D Ellison, T D Johnston, T Waid, J W McKeown, B Lucus, and D Ranjan: Patient survival following simultaneous kidney-pancreas transplantation (TX) versus kidney TX alone in patients with type I diabetes mellitus and renal failure. International Society of Transplantation, 2000

36 Butros R, S Reddy, T Johnston, D Ranjan, T Waid, J W McKeown, P Sawaya, and Bruce Lucas: Successful renal transplantation using kidneys from diabetic cadaver donors. JASN 11: 2000 681A Accepted for presentation.

37 Johnson, T, S Reddy, T Waid, J McKeown, B Lucas, J Thompson and D Ranjan: Prevention of acute rejection in pancreas transplant recipients using T10B9: A Pilot study. ACTA Chir. Austriaca Vol 33. Suppl. 174, pg 15, 2001

38 Reddy, K, D Davies, D Ormond, T Johnston, T Waid W MdKeown, B Lucas and D Ranjan: Impact of acute rejection episodes on the long-term graft survival in kidney-pancreas transplant recipients. ACTA Chir. Austriaca Vol 33 Suppl 174, pg 14, 2001

*Selected for Presentation

GRANT ACTIVITY

GRANTS RECEIVED:

Date	Source	Title	Project Title	Amounts
1983-86	VA Merit Review	PI	The Role of Calcium Mediator of Hormonal Action in Renal Tubules	\$55,600 \$102,840
1985-86	DCI	PI	The Role of Calcium in Stimulus Response	\$53,573

			Coupling of Hormonal Action in Tenal Tubles	
--	--	--	--	--

GRANTS SUBMITTED:

90-94	NIH	PI CO-PI	Brian A. Jackson, Ph.D. J. Wade McKeown, M.D. Vasopressin and Thick Ascending Limb Function \$692,063
90-93	V.A Merit Review	PI CO-PI	J. Wade McKeown, M.D. Brian A. Jackson, Ph.D. Vasopressin and Thick Ascending Limb Function \$278,837
	NIH	PI CO-PI CO-PI	O.H. Coburn, Ph.D. Brian A. Jackson, Ph.D. J. Wade McKeown, M.D. Functional Mechanisms of Aminoglycoside Nephro-toxicity \$402,792

RESEARCH PROJECTS

Investigator: Phase II Study using T10 B9, 1A-31 for reversal of acute renal allograft rejection

Investigator: Sandimmune Neoral® Study N103

Investigator: T10 B9, 1A-31 for induction of immunosuppression or treatment for rejection in heart transplantation

Investigator: Multicenter, double blind, randomized, placebo-controlled, dose-finding, safety, and tolerability trial of recombinant human insulin-like growth factor (rhIGF-I) in patients with acute kidney failure.

Co-investigator: The use of cytomegalovirus hyperimmune gammaglobulin (CytoGam) in highly or specifically sensitized thoracic organ transplant candidates.

Co-investigator: “A Phase III, Randomized, Double-Blind, Placebo Controlled Multicenter Study of the Efficacy of Odulimomab (ANTILFA™) In Preventing Delayed Graft Function of Cadaveric Renal Allografts in Patients Not Receiving Biological Induction Therapy.” Protocol Number AFO12396.

Sponsor: Pasteur Merieux Connaught
Funding: \$69,480 (Actual)
10 subjects projected, 9 subjects enrolled
Open date: 11/17/97
Closure date: 7/27/00

Co-investigator: “An Open Label, Comparative Trial of Two Daclizumab Dosing Strategies versus No Induction in Combination with Tacrolimus, Mycophenolate Mofetil, and Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant (SKPT) Recipients.” Protocol Number ZEN-049.

Sponsor: University of Tennessee, Memphis
Funding: \$58,500 (actual)
10 subjects projected, 9 subjects enrolled
Open date: 3/17/99
Closure date: 10/02

Co-investigator: “A Phase II Open Label Study of MedImmune T10B9 In The Induction of Immunosuppression for Combined Kidney and Pancreas Transplantation.”

Sponsor: MedImmune/University of Kentucky
Funding: None
12 subjects enrolled
Open date: 4/3/98
Closure date: 12/31/00

Co-investigator: “Controlled, Randomized, Open Label, Multicenter Study Comparing SANG 35 Oral Solution with Neoral® Capsules in De Novo Adult Renal Allograft Recipients.” Protocol Number SMC-539-1011.

Sponsor: SangStat Medical Corporation
Funding: \$18,750 (actual)
15 subjects projected, 5 subjects enrolled
Open date: 10/21/98
Closure date: 3/9/00

Co-investigator: “Prograf (tacrolimus) as Secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure “ Protocol 20-98-002.

Sponsor: Fujisawa Healthcare Incorporated
Funding: \$256,000 (actual)

15 subjects projected, 32 subjects enrolled
Open date: 5/3/99
Closure date: 10/05 (projected)

Co-investigator: A Prospective, Randomized Multicenter Double-blind Study of Early Corticosteroid Cessation vs Long-term Maintenance Corticosteroid Therapy With thymoglobulin, Prograf and Cellcept in Primary Renal Transplant Recipients.” Protocol Number 20-99-001.

Sponsor: Fujisawa Healthcare Incorporated
Funding: \$120,000 (projected)
20 subjects projected
Open date: 8/25/01 (IRB approval)
Closure date: 11/06 (projected)

Principal Investigator: “A Phase II, Randomized, Multicenter, Open-label Safety Study of ISA tx 247 and Cyclosporine (NEORAL) in Post-Renal Transplant Patients.” Protocol Number ISA00-16.

Sponsor: Isotechnika, Incorporated
Funding: \$61,940.55 (projected)
4 subjects projected
Open date: 10/08/01 (IRB approval)
Closure date: 9/30/02

Sub-Investigator: “A Follow-up to the Multicenter Phase II Comparative Trial of Thymoglobulin versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.” Protocol SMC-101-1010.

Sponsor: Sangstat Medical Corporation
Open date: 2002.

Sub-Investigator: “An Open-Label Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil: MMF (CellCept) and sirolimus (Rapamune).” Protocol ML 17140/01265.

Sponsor: Hoffmann-LaRoche Limited, Incorporated
Open date: 2003

Sub-Investigator: “A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/ MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in de novo Kidney Transplant Recipients.” Protocol 02-0-158

Sponsor: Fujisawa Healthcare, Incorporated

Open date: 2003.

Sub-Investigator: “A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients.” Protocol 0468H1-316-US.

Sponsor: Wyeth-Ayerst Research
Open date: 2001

Principal Investigator: “A Prospective, Randomized, Open-label, Twenty-six Week Study of the Efficacy and Safety of Converting Kidney and Liver Transplant Recipients with Tacrolimus-Associated Abnormal Glucose Metabolism to Neoral with C2 Monitoring.” Protocol COLO 400A US 06.

Sponsor: Novartis Pharmaceuticals Corporation
Open date: 2003

Sub-Investigator: “A Double-Blind, Placebo-Controlled, Multi-center, Dose-Ranging Study of an Anti-T-Lymphocyte Immune Globulin (EZ-2053) in Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s).” Enzon Pharmaceuticals, 2004. – *Clinical Study Coordinator*

Sub-Investigator: “An Open-Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs. Concentration Controlled CellCept® Regimens for Patients Following a Single Organ Renal Transplantation in Combination with Full Dose and Reduced Dose Calcineurin Inhibitors.” Protocol ML17225A/01265. *Clinical Study Coordinator*

Sponsor: F. Hoffman-LaRoche Limited, Incorporated
Open date: 2005

Principal Investigator: “A Phase IIB, Randomized, Multi-Center, Open-Label, concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf®) in *De Novo* Renal Transplant Patients Protocol ISA05-01. Isotechnika Incorporated, 2005.

Sponsor: Isotechnika, Inc.
Open date: 2005

Sub-Investigator: “A Phase IV, Randomized, Open-Label, Comparative, Multi-center Study to Assess the Safety and Efficacy of Induction Agents Alemtuzumab (Campath 1H®), Basiliximab (Simulect®), or Rabbit Anti-Thymocyte Globulin (Thymoglobulin®) in Combination with Tacrolimus (Prograf), Mycophenolate Mofetil (Cellcept), and a Rapid Steroid Withdrawal in Renal Transplant Recipients.” Protocol 20-04-003. *Clinical Study Coordinator*

Sponsor: Astellas Pharma US

Open date: 2005

Sub-Investigator: Diabetes Incidence after Renal Transplantation: Neoral C-2 Monitoring versus Tacrolimus -200 “A six month Open-Label, Multi-center, Randomized study to compare the incidence of new onset diabetes mellitus and glucose metabolism in patients receiving Neoral with C-2 monitoring versus tacrolimus after de novo kidney.

Sponsor: Novartis

Sub-Investigator: “A Randomized, Open-Label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in *De Novo* Renal Allograft Recipients.

Sponsor: Wyeth-Orion

Sub-Investigator: A 24-month, Multi-center, Randomized, Open-Label Non-Inferiority Study of Efficacy and Renal Function Comparing Concentration-Controlled Certican in Two Doses (1.5 mg/day and 3.0 mg/day) with Reduced Neoral Versus 1.44 mg Myfortic with Standard Dose Neoral in *De Novo* Renal Transplant Recipients (Novartis Crad001A2309).

Sponsor: Novartis

Co Investigator: “A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf®(Tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral®(Cyclosporin)/MMF in de novo Kidney Transplant Recipients” Astellas Protocol 02-0-158

Principal Investigator: “A Phase IIB, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus, (Prograf®) in de novo Renal Transplant Patients (ISA05-01)” Isotechnika Protocol ISA05-01

Co_Investigator: “An Open Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal In Recipients of Primary Renal Allografts Maintained Long-Term On Mycophenolate Mofetil and Sirolimus” Roche Protocol ML17140/01265

Co-Investigator: “A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients” Astellas Pharma Protocol 0485-CL-U201